Literature DB >> 17909921

Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome.

Valerie A Williams1, Thomas J Watson, Fernando A Herbella, Oliver Gellersen, Daniel Raymond, Carolyn Jones, Jeffrey H Peters.   

Abstract

BACKGROUND: The increasing adoption of endoscopic therapies and expectant surveillance for patients with high grade dysplasia (HGD) in Barrett's esophagus has created considerable controversy regarding the ideal treatment choice. Confusion may be due, in part, to a limited understanding of the outcomes associated with surgical resection for HGD and extrapolation of data derived from patients undergoing an esophagectomy for invasive cancer. The purpose of our study was to document the perioperative and symptomatic outcomes and long-term survival after esophagectomy for HGD of the esophagus.
MATERIAL AND METHODS: The study population consisted of 38 patients who underwent esophagectomy for biopsy-proven HGD between 10/1999 and 6/2005. Three patients were excluded from analysis due to obvious tumor on upper endoscopy. Patients were evaluated regarding ten different foregut symptoms and administered a ten-question appraisal of eating and bowel habits. Outcome measures included postoperative morbidity and mortality, the prevalence of invasive cancer in the esophagectomy specimens, symptomatic and functional alimentary results, patient satisfaction, and long-term survival. Median follow-up was 32 months (range, 7-83).
RESULTS: Thirty-day postoperative and in-hospital mortality was zero. Complications occurred in 37% (13/35), and median length of stay was 10 days. Occult adenocarcinoma was found in 29% (10/35) of surgical specimens (intramucosal in four; submucosal in five; and intramuscular in one with a single positive lymph node.) Patients consumed a median of three meals per day, most (76%, 26/34) had no dietary restrictions, and two-thirds (23/34) considered their eating pattern to be normal or only mildly impacted. Meal size, however, was reported to be smaller in the majority (79%, 27/34) of patients. Median body mass index (BMI) decreased slightly after surgery (28.6 vs 26.6, p>0.05), but no patient's BMI went below normal. The number of bowel movements/day was unchanged or less in a majority (82%) of patients after surgery. Fifteen of 34 (44%) patients reported loose bowel movements, which occurred less often than once per week in 10 of the 15. One patient had symptoms of dumping. Mean symptom severity scores improved for all symptoms except dysphagia and choking. Four patients developed foregut symptoms that occurred daily. Most patients (82%) required at least one postoperative dilation for dysphagia. Almost all (97%) patients were satisfied. Disease-free survival was 100%, and overall survival was 97% (34/35) at a median of 32 months.
CONCLUSION: Esophagectomy is an effective and curative treatment for HGD and can be performed with no mortality, acceptable morbidity, and good alimentary outcome. These data provide a gold standard for comparison to alternative therapies.

Entities:  

Mesh:

Year:  2007        PMID: 17909921     DOI: 10.1007/s11605-007-0330-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  44 in total

1.  Hospital volume and surgical mortality in the United States.

Authors:  John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

2.  Outcomes after esophagectomy: a ten-year prospective cohort.

Authors:  Stephen H Bailey; David A Bull; David H Harpole; Jeffrey J Rentz; Leigh A Neumayer; Theodore N Pappas; Jennifer Daley; William G Henderson; Barbara Krasnicka; Shukri F Khuri
Journal:  Ann Thorac Surg       Date:  2003-01       Impact factor: 4.330

3.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

4.  Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett's oesophagus.

Authors:  Vijay Sujendran; Giuseppe Sica; Bryan Warren; Nicholas Maynard
Journal:  Eur J Cardiothorac Surg       Date:  2005-09-26       Impact factor: 4.191

5.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

6.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

Authors:  E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

7.  Barrett's esophagus: development of dysplasia and adenocarcinoma.

Authors:  W Hameeteman; G N Tytgat; H J Houthoff; J G van den Tweel
Journal:  Gastroenterology       Date:  1989-05       Impact factor: 22.682

8.  Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients.

Authors:  R G Lee
Journal:  Am J Surg Pathol       Date:  1985-12       Impact factor: 6.394

9.  Outcomes of dysplasia arising in Barrett's esophagus: a dynamic view.

Authors:  Renato Romagnoli; Jean-Marie Collard; Christian Gutschow; Nadine Yamusah; Mauro Salizzoni
Journal:  J Am Coll Surg       Date:  2003-09       Impact factor: 6.113

10.  High-grade dysplasia in the columnar-lined esophagus.

Authors:  N K Altorki; M Sunagawa; A G Little; D B Skinner
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

View more
  26 in total

1.  Radiofrequency ablation for dysplasia in Barrett's esophagus restores β-catenin activation within esophageal progenitor cells.

Authors:  K Krishnan; S Komanduri; J Cluley; R Dirisina; P Sinh; Jeff Z Ko; L Li; R B Katzman; T A Barrett
Journal:  Dig Dis Sci       Date:  2011-09-24       Impact factor: 3.199

2.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

Review 3.  Management of high-grade dysplasia.

Authors:  Francesco Palazzo; Piero M Fisichella; Marco G Patti
Journal:  Curr Gastroenterol Rep       Date:  2008-06

Review 4.  Endotherapy for Barrett's esophagus with high-grade dysplasia and intramucosal carcinoma.

Authors:  Drew B Schembre
Journal:  J Gastrointest Surg       Date:  2009-03-26       Impact factor: 3.452

Review 5.  SSAT controversies intramucosal esophageal cancer and high-grade dysplasia: which treatment? Surgical therapy: improved outcomes and piece of mind.

Authors:  Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2009-03-18       Impact factor: 3.452

6.  Endoscopic management of early esophageal neoplasia: an emerging standard.

Authors:  Kelly M Galey; Candice L Wilshire; Thomas J Watson; Marabel D Schneider; Vivek Kaul; Carolyn E Jones; Virginia R Litle; Asad Ullah; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2011-08-03       Impact factor: 3.452

Review 7.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

Review 8.  [Early esophageal cancer: pro surgical resection].

Authors:  H J Stein; M Schweigert; A Dubecz
Journal:  Chirurg       Date:  2011-06       Impact factor: 0.955

Review 9.  Preemptive surgery for premalignant foregut lesions.

Authors:  Rohit R Sharma; Mark J London; Laura L Magenta; Mitchell C Posner; Kevin K Roggin
Journal:  J Gastrointest Surg       Date:  2009-06-10       Impact factor: 3.452

10.  Minimally invasive esophagectomy.

Authors:  Christy M Dunst; Lee L Swanström
Journal:  J Gastrointest Surg       Date:  2009-09-30       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.